Behcet's Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports
DelveInsight's 'Behcet's Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Behcet's Disease, historical and forecasted epidemiology as well as the Behcet's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Some of the key facts of the Behcet's Disease Market Report:
The Behcet's Disease market size was value ~USD 140 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Christopher J. Schaber, PhD, President and CEO of Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, stated that the company remains committed to advancing its diverse clinical pipeline. Key upcoming milestones include the anticipated top-line results in 2026 from the ongoing confirmatory Phase 3 placebo-controlled trial evaluating HyBryte™ (synthetic hypericin) for early-stage cutaneous T-cell lymphoma (CTCL). Additionally, in the latter half of this year, Soligenix expects to announce top-line data from its ongoing Phase 2 trials of SGX945 (dusquetide) for Behçet's disease and SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
In November 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with unmet medical needs, announced the initiation of patient enrollment for its Phase 2 clinical trial (protocol number DUS-AUBD-01) assessing SGX945 (dusquetide) as a treatment for Behçet's Disease.
Among the EU4 and the UK, Italy has the largest market size at around USD 10 million, followed by France with approximately USD 8 million. These figures are anticipated to change over the forecast period (2024-2034) due to ongoing research and development efforts, which may result in the discovery of more effective treatments for Behcet's Syndrome.
In January 2024, Soligenix announced that the US Food and Drug Administration (FDA) has granted fast track designation to SGX945 (dusquetide)
In 2023, Japan had the highest number of diagnosed prevalent cases of Behcet's syndrome among the 7MM countries.
In 2023, Italy had the highest number of diagnosed prevalent cases among the EU4 and the UK, with approximately 7,000 cases. This number is expected to increase by 2034.
In 2023, the total diagnosed prevalent cases of Behcet's Syndrome in the US were approximately 3,500 for pediatric patients and around 16,000 for young adults.
Among the clinical manifestations of Behcet's Syndrome in the US, oral ulcers were the most prevalent, representing about 30% of the total cases, followed by genital ulcers.
In the EU4 countries and the UK, oral ulcers were the most common, with approximately 5,000 cases, followed by genital ulcers, which accounted for around 3,000 cases.
Key Behcet's Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
Key Behcet's Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
The Behcet's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Behcet's Disease pipeline products will significantly revolutionize the Behcet's Disease market dynamics.
Behcet's Disease Overview
Behcet's Disease is a rare, chronic, and multisystem inflammatory disorder characterized by recurring episodes of inflammation affecting various parts of the body. It is named after the Turkish dermatologist Hulusi Behçet, who first described the condition in 1937. The disease primarily affects blood vessels, causing symptoms that can involve the mouth, eyes, skin, joints, and other organs.
Behcet's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Behcet's Disease Epidemiology Segmentation:
The Behcet's Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Diagnosed Prevalent Cases of Behcet's Syndrome in the 7MM
Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in the 7MM
Clinical Manifestations Associated With Behcet's Syndrome in the 7MM
Total Patients Seeking Treatment for Behcet's Syndrome in the 7MM
Download the report to understand which factors are driving Behcet's Disease epidemiology trends @ Behcet's Disease Epidemiology Forecast
Behcet's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Behcet's Disease market or expected to get launched during the study period. The analysis covers Behcet's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Behcet's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Behcet's Disease Therapies and Key Companies
SGX945: Soligenix
RAY121: Chugai Pharmaceutical
Dusquetide: Soligenix
Filgotinib: UMC Utrecht
Hemay005: Ganzhou Hemay Pharmaceutical
Apremilast: Amgen
Discover more about therapies set to grab major Behcet's Disease market share @ Behcet's Disease Treatment Landscape
Behcet's Disease Market Strengths
The constant efforts by researchers to determine clear molecular pathogenesis are progressively increasing.
Studies suggest that Behcet's syndrome shares common features with autoimmune and inflammatory disorders, thus leading to the detection of the main mediators involved in the pathomechanism of Behcet's syndrome.
Behcet's Disease Market Opportunities
There is an attractive market for therapies with a primary goal of treatment to rapidly suppress and prevent new inflammatory attacks to avoid irreversible organ damage, especially in the early, active stages of Behcet's syndrome.
As a consequence of escalating knowledge and awareness among providers and caregivers about Behcet's syndrome, the prevalence of the disease is increasing, which may further expedite the R&D.
Scope of the Behcet's Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Behcet's Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
Key Behcet's Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
Behcet's Disease Therapeutic Assessment: Behcet's Disease current marketed and Behcet's Disease emerging therapies
Behcet's Disease Market Dynamic s: Behcet's Disease market drivers and Behcet's Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Behcet's Disease Unmet Needs, KOL's views, Analyst's views, Behcet's Disease Market Access and Reimbursement
Table of Contents
1. Behcet's Disease Market Report Introduction
2. Executive Summary for Behcet's Disease
3. SWOT analysis of Behcet's Disease
4. Behcet's Disease Patient Share (%) Overview at a Glance
5. Behcet's Disease Market Overview at a Glance
6. Behcet's Disease Disease Background and Overview
7. Behcet's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Behcet's Disease
9. Behcet's Disease Current Treatment and Medical Practices
10. Behcet's Disease Unmet Needs
11. Behcet's Disease Emerging Therapies
12. Behcet's Disease Market Outlook
13. Country-Wise Behcet's Disease Market Analysis (2020–2034)
14. Behcet's Disease Market Access and Reimbursement of Therapies
15. Behcet's Disease Market Drivers
16. Behcet's Disease Market Barriers
17. Behcet's Disease Appendix
18. Behcet's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
KISQALI Achieves Significant Market Growth, Strengthening Its Position in Breast Cancer and CDK4/6 Inhibitors Segment
KISQALI is a promising CDK4/6 inhibitor used in combination with aromatase inhibitors for the treatment of HR-positive, HER2-negative breast cancer. Its market potential remains strong, driven by its efficacy in prolonging progression-free survival in early and metastatic stages of the disease. With a growing demand for targeted therapies and increasing patient awareness, KISQALI's market is expected to expand further. DelveInsight's ' KISQALI Market Size, Forecast, and Market Insight Report ' highlights the details around KISQALI, a cyclin-dependent kinase (CDK4/6 inhibitor). The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of KISQALI. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Novartis' KISQALI (ribociclib) Overview KISQALI (ribociclib) is a targeted cyclin-dependent kinase inhibitor, a type of drug that helps slow cancer progression by blocking two proteins, cyclin-dependent kinase 4 and 6 (CDK4/6). When these proteins are overactive, they can cause cancer cells to grow and divide too quickly. By specifically targeting CDK4/6, KISQALI aims to prevent cancer cells from replicating uncontrollably. KISQALI was developed by Novartis in collaboration with Astex Pharmaceuticals. In addition to its FDA approval for early breast cancer (EBC) patients in the US, KISQALI is undergoing regulatory reviews in other regions, including the EU and China. KISQALI has received approval for treating metastatic breast cancer (MBC) in 99 countries, including the US and EU. In the US, it is approved for adults with HR+/HER2- advanced or MBC in combination with an aromatase inhibitor (AI) as initial endocrine therapy (ET) or fulvestrant as initial ET or after disease progression. In the EU, it is approved for women with HR+/HER2- advanced or MBC in combination with an AI or fulvestrant as initial ET or after disease progression. In pre- or peri-menopausal women, the ET should be combined with a luteinizing hormone-releasing hormone agonist. In the context of MBC, KISQALI has consistently shown significant overall survival benefits in three Phase III trials. The NCCN Guidelines for breast cancer recommend KISQALI (ribociclib) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment in HR+/HER2- patients when combined with an AI, making KISQALI the preferred first-line treatment in the US for this patient group. Additionally, KISQALI received the highest score among CDK4/6 inhibitors on the ESMO Magnitude of Clinical Benefit Scale, scoring five out of five for first-line treatment of pre-menopausal patients with HR+/HER2- advanced breast cancer. KISQALI, when combined with either letrozole or fulvestrant, earned a four out of five rating for post-menopausal patients with HR+/HER2- advanced breast cancer in the first-line setting. KISQALI Dosage and Administration The suggested KISQALI dosage is 600 mg (equivalent to three 200 mg film-coated tablets) taken orally once a day for 21 consecutive days, followed by a 7-day break from treatment, making a full cycle of 28 days. KISQALI can be taken with or without food. When used in combination with KISQALI, the recommended dose of fulvestrant is 500 mg, administered on Days 1, 15, 29, and then once a month thereafter. KISAQALI at a Glance Drug Name: KISQALI (ribociclib) Molecule type: Small molecule Developer: Novartis Primary Indication: HR+/HER2− breast cancer Mechanism of action: Cyclin-dependent kinases 4 and 6 inhibitor Route of administration: Oral CDK4/6 inhibitors are a type of targeted cancer therapy that work by blocking the function of cyclin-dependent kinases 4 and 6—enzymes crucial for regulating the cell cycle, particularly the progression from the G1 to S phase, where cells begin DNA replication. By inhibiting these kinases, the drugs effectively stop cancer cell proliferation, leading to growth arrest and potentially cell death. This precise mechanism makes them especially effective in treating hormone receptor-positive, HER2-negative breast cancers, among other types. The introduction and approval of CDK4/6 inhibitors have significantly reshaped the treatment approach for HR+/HER2− metastatic breast cancer. Currently, three main selective CDK4/6 inhibitors, IBRANCE (palbociclib), KISQALI (ribociclib), and VERZENIO (abemaciclib), are commonly used in combination with endocrine therapy as the first-line treatment. Notably, the NCCN now recommends KISQALI as the preferred first-line option for metastatic cases. Once endocrine and targeted therapies no longer work, chemotherapy and antibody-drug conjugates (ADCs) are typically used. IBRANCE remains the market leader among CDK4/6 inhibitors, with around 70% of U.S. patients receiving it when prescribed a drug in this class. Looking ahead, there is strong potential to extend the use of CDK4/6 inhibitors beyond HR+/HER2− advanced breast cancer. According to DelveInsight, market growth in the 7MM is expected to be fueled by rising cancer incidence, greater awareness and access to treatment, and an active pipeline of new indications. Emerging Competitors of KISQALI Some of the CDK4/6 inhibitors in the pipeline include Lerociclib (G1 Therapeutics and Pepper Bio), Atirmociclib (Pfizer), PRT3645 (Prelude Therapeutics), Trilaciclib (G1 Therapeutics), SPH4336 (Shanghai Pharma Biotherapeutics), Dalpiciclib (Jiangsu Hengrui Pharmaceuticals), BGB-43395 (BeiGene), BTX-9341 (Biotheryx), and Euthare-155008 (Shengke Pharmaceuticals), among others. In May 2024, G1 Therapeutics and Pepper Bio announced a global licensing agreement (excluding Asia-Pacific) for lerociclib, a selective CDK4/6 inhibitor. Using their COMPASS platform, Pepper Bio identified CDK4/6 as key targets for Hepatocellular carcinoma, with preclinical models showing superior efficacy. Lerociclib is now advancing to Phase II trials. Key Milestones of KISQALI In December 2024, Novartis shared updated findings from the pivotal Phase III NATALEE trial of KISQALI, highlighting its prolonged effectiveness even after treatment ends when used alongside endocrine therapy (ET). The results demonstrated a 28.5% sustained reduction in the risk of distant recurrence (HR=0.715; 95% CI 0.604–0.847; nominal P<0.0001) compared to ET alone in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC). In November 2024, Novartis announced that the European Commission (EC) had approved KISQALI, in combination with an aromatase inhibitor (AI), for use as adjuvant treatment in patients with HR-positive HER2-negative early breast cancer who are at high risk of recurrence. In September 2024, Novartis announced that the FDA has approved KISQALI, in combination with an aromatase inhibitor (AI), for adjuvant treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) who are at high risk of recurrence — including individuals with node-negative (N0) disease. In September 2020, Novartis proudly shared that KISQALI received the highest possible score—five out of five—on the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale (ESMO-MCBS) for use as a first-line treatment in premenopausal patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. In July 2018, Novartis received a new approval from the FDA for KISQALI (ribociclib) to treat women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced or metastatic breast cancer. In March 2017, the FDA approved KISQALI, in combination with an aromatase inhibitor, as a first-line endocrine-based treatment for postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2−) advanced or metastatic breast cancer. Discover how KISQALI CDK4/6 inhibitor is shaping the breast cancer treatment landscape @ KISQALI Cost KISQALI Market Dynamics KISQALI (ribociclib) is a CDK4/6 inhibitor used primarily in the treatment of HR-positive, HER2-negative breast cancer. Since its approval in 2017 by the FDA, it has become a key player in the competitive oncology market. The drug works by inhibiting cyclin-dependent kinases 4 and 6, which are responsible for the progression of many cancers, including breast cancer. KISQALI is typically used in combination with aromatase inhibitors or letrozole, offering a therapeutic advantage by enhancing anti-tumor efficacy while also maintaining manageable safety profiles. The market dynamics for KISQALI are heavily influenced by the broader competitive landscape of CDK4/6 inhibitors, with notable competitors including IBRANCE (palbociclib) and VERZENIO (abemaciclib). These drugs are all vying for market share in a segment that is expected to grow significantly due to increasing breast cancer diagnoses and the demand for targeted therapies. KISQALI has carved a niche for itself with favorable clinical trial data, including its ability to deliver improved progression-free survival rates, which is appealing to oncologists and healthcare providers. However, pricing pressures, especially in markets with significant healthcare budget constraints, and the rising popularity of combination therapies will influence KISQALI's market position in the coming years. Additionally, ongoing research and the potential for new indications could further shape KISQALI's growth trajectory. Table of Contents 1. Report Introduction 2. KISQALI: Novartis 2.1. Product Overview 2.2. Other Development Activities 2.3. Clinical Development 2.4. Clinical Trials Information 2.5. Safety and Efficacy 2.6. Product Profile 2.7. Market Assessment 2.7.1. The 7MM Analysis 2.7.1.1. Cost Assumptions and Rebate 2.7.1.2. Pricing Trends 2.7.1.3. Analogue Assessment 2.7.1.4. Launch Year and Therapy Uptake 2.7.2. The United States Market Analysis 2.7.3. EU4 and the United Kingdom Market Analysis 2.7.3.1. Germany 2.7.3.2. France 2.7.3.3. Italy 2.7.3.4. Spain 2.7.3.5. UK 2.7.4. Japan Market Analysis 2.8. Market Drivers 2.9. Market Barriers 2.10. SWOT Analysis 3. Key Cross of Marketed Competitors of KISQALI 4. Key Cross of Emerging Competitors of KISQALI Related Reports CDK4/6 Inhibitor Market CDK4/6 Inhibitor Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDK4/6 inhibitor companies, including Pfizer, Prelude Therapeutics, G1 Therapeutics, Pepper Bio, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Sandeep Joshi Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Cision Canada
a day ago
- Cision Canada
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
VANCOUVER, BC, July 22, 2025 /CNW/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation of their solutions in the real world. Among the players that are moving closer to major milestones include Avant Technologies, Inc. (OTCQB: AVAI), Agenus Inc. (NASDAQ: AGEN), Clover Health Investments, Corp. (NASDAQ: CLOV), Zimmer Biomet Holdings, Inc. (NYSE: ZBH), and Monogram Technologies Inc. (NASDAQ: MGRM). Currently, the AI in healthcare sector projected to surpass $110 billion by 2030. However, according to Accenture, artificial intelligence could unlock an additional $461 billion in value across healthcare by 2035—on top of a sector already projected to surpass $2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech are continuing to raise visibility for their AI-powered diagnostic platform, with Ainnova CEO Vinicio Vargas recently featured as a speaker at Roche's"Macular Spectacular" Ophthalmology Conference in Cartagena, Colombia. The event brought together leading voices in visual health from across Latin America, with discussions focused on advancing patient outcomes through AI innovation. Vargas, who also sits on the board of Ai-nova Acquisition Corp. (AAC), presented Vision AI as a transformative tool to expand access to early diabetic retinopathy screening and reduce preventable blindness throughout the region. Vargas also highlighted a Q4 2024 alliance with Roche and prepaid‑health‑plan provider Salud 360 that is piloting Vision AI among high‑risk diabetic patients; if successful, the program will be rolled out in the United States, Canada, and Europe through Ai ‑ nova Acquisition Corp. (AAC), which holds worldwide rights to Ainnova's technology portfolio . This momentum builds on a recent regulatory breakthrough in the U.S. market. Avant and Ainnova recently completed a key pre-submission meeting with the FDA for Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases. "We're truly excited about this next phase," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists. The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI. The FDA session offered clear feedback on study design, site selection, and execution strategy—enabling Ainnova and its clinical trial partner, Fortrea, to finalize preparations for U.S.-based trials. "This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera," added Vargas. "We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care." While regulatory efforts advance in the U.S., the company has already launched a groundbreaking chronic care model across Latin America. The program, now live through Grupo Dökka's Fischel and La Bomba pharmacy chains, offers free, walk-in retinal risk assessments—delivering real-time AI results and connecting at-risk patients directly with clinics and specialists. Over 30% of diabetics develop diabetic retinopathy, a leading cause of preventable blindness. Vision AI offers early, low-cost screening without the need for an ophthalmologist onsite. The model has gained support from pharmacies, insurers, and pharmaceutical partners—demonstrating real traction across the healthcare value chain. Avant' s role in these efforts continues to grow. Through Ai-nova Acquisition Corp., which it co-founded and structured, Avant maintains global licensing rights to Ainnova's platform and stands to benefit from both U.S. and international commercialization. The Latin American pilot programs are already generating momentum, with U.S. trials positioned to unlock a vastly larger market. The company is also preparing a standalone venture to house a potential therapeutic candidate for diabetes—bringing leadership, data, and IP into one streamlined structure for diagnostics and treatment alike. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova's future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer's, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. A structural simplification may be on the horizon as well. A previously announced non-binding LOI remains active for Avant to acquire 100% of Ainnova Tech —potentially consolidating all IP, leadership, and commercial rights under one public entity. Such a move would give investors pure-play exposure to this fast-evolving tech stack, while deepening operational alignment between the firms. Agenus Inc. (NASDAQ: AGEN) has partnered with AI biotech firm Noetik to develop predictive biomarkers for its cancer immunotherapy combo BOT/BAL. "At Agenus, we are committed to transforming cancer care through scientific innovation and next-generation immunotherapies," said Dr. Garo Armen, Chairman and CEO of Agenus. "This collaboration with Noetik enables us to harness cutting-edge AI to better understand patient biology and tailor treatments more precisely." By using Noetik's advanced "virtual cell" models trained on massive tumor datasets, the collaboration aims to identify which patients are most likely to benefit from treatment. This could improve clinical trial outcomes and accelerate personalized cancer care using AI-driven insights Clover Health Investments, Corp. (NASDAQ: CLOV) recently launched a new pharmacy pilot program across New Jersey in partnership with IPC's iCare+ network. The initiative enables local pharmacies to use AI tools and real-time data to help seniors manage medications and reduce hospital visits. "This is more than a new program—it's a new model for how we support our New Jersey members," said Jamie Reynoso, CEO of Medicare Advantage at Clover Health. "By working with the pharmacists who are already embedded in our communities, we can deliver better care, deliver amazing customer experiences and support the independent businesses that keep New Jersey strong." It's part of Clover's strategy to deliver more personal, community-based healthcare while supporting independent pharmacies Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered a definitive agreement to acquire Monogram Technologies Inc. (NASDAQ: MGRM) for approximately US$177 million in cash, with additional milestone-based payments up to US$12.37 per share. " Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons – now and into the future. With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery." The acquisition adds Monogram's semi- and fully autonomous orthopedic robotics to Zimmer Biomet's ROSA® platform, aiming to create the most comprehensive robotics suite in the orthopedic space. Monogram's FDA-cleared knee arthroplasty robot is expected to commercialize in 2027, with a fully autonomous version in development. "Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty," said Benjamin Sexson, CEO of Monogram. "We are thrilled by the opportunity to add our technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale." Zimmer Biomet expects the deal to be accretive by 2028, supporting long-term growth in the high-demand surgical robotics market. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
a day ago
- Cision Canada
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
NEW YORK, /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth. The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma, is a significant factor driving the adoption of AI in ophthalmology. As the population ages, the incidence of these diseases increases, creating a need for efficient and accurate diagnostic tools. For instance, according to the CDC, the estimated number of Americans living with glaucoma in 2022 was 4.22 million. AI algorithms can rapidly analyze complex retinal images, facilitating early detection and treatment. For instance, AI systems have shown high sensitivity and specificity in identifying diabetic retinopathy, which allows for timely interventions and reduces the risk of vision loss. Moreover, integrating advanced imaging techniques such as Optical Coherence Tomography (OCT) with AI has revolutionized ophthalmic diagnostics. High-resolution imaging provides detailed views of ocular structures, which enhances diagnostic precision when analyzed by artificial intelligence (AI). The availability of large datasets from these imaging technologies allows for the training of robust AI models, improving their accuracy and reliability in clinical settings." Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB: AVAI), Alcon Inc. (NYSE: ALC), Bausch + Lomb Corporation (NYSE: BLCO), Johnson & Johnson (NYSE: JNJ), Tempus AI, Inc. (NASDAQ: TEM). Research And Markets continued: "Furthermore, teleophthalmology, the remote delivery of eye care services, has gained traction, especially in underserved regions. AI is crucial in this expansion by enabling automated analysis of retinal images, facilitating remote diagnosis, and reducing the need for in-person consultations. This approach increases access to eye care and optimizes resource utilization in healthcare systems. For instance, in June 2024, C3 Med-Tech, an ophthalmic health tech startup, raised USD 0.23 million to launch AI-enabled, portable eye screening devices. The funding is expected to support telemedicine integration, real-time disease detection, and expansion across India, aiming to reduce avoidable blindness, especially in underserved communities facing a shortage of ophthalmologists. Moreover, AI's ability to analyze and interpret data from Electronic Health Records (EHRs) facilitates personalized treatment plans in ophthalmology. AI predicts disease progression by assessing patient history, genetic information, and imaging data and recommends tailored interventions, further contributing to market growth." Avant Technologies, Inc. (OTCQB: AVAI) Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference - Avant Technologies, Inc. ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Cartagena, Colombia. The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in Latin America. Ainnova's CEO, Vinicio Vargas, who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego, Hugo Ocampo, and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems. In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova's AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy. If the program is successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through AAC. AAC has the worldwide licensing rights for Ainnova's technology portfolio, which includes Ainnova's Vision AI platform. In other diabetes developments and happenings in the biotech market include: Alcon Inc. (NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, recently announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. "Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone," said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. "We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients." Bausch + Lomb Corporation (NYSE: BLCO), a leading global eye health company dedicated to helping people see better to live better, recently launched"Eyes Tell the Story: The Impact of Dry Eye." The campaign aims to educate about dry eye through personal stories, compelling imagery and new survey data, and encourages people with symptoms to speak with their eye doctor to find relief. Eyes Tell the Story builds upon Know Your Dry Eye, an educational campaign launched in 2024 that featured data and insights from the company's first State of Dry Eye survey, which showed the majority of Americans may not know that their eye symptoms are associated with eye dryness, despite the growing prevalence of dry eye. This year's survey, conducted among dry eye sufferers who are using either a prescription treatment or over-the-counter (OTC) product, further supports the need for more patient education and to dispel ongoing misconceptions surrounding dry eye. Johnson & Johnson (NYSE: JNJ) recently launched TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The TECNIS Odyssey IOL was first launched in the US in October 2024. The TECNIS Odyssey IOL is a full vision range intraocular lens (IOL), built on the TECNIS platform from Johnson & Johnson, which, according to the company, provides 2 times better contrast in low lighting than PanOptix. The TECNIS Odyssey combines advanced optics and proprietary materials, offering consistently clear, high-contrast vision, according to the company. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared ECG-AI device in Tempus' growing suite of next generation devices designed to identify patients at risk for a variety of cardiovascular conditions. "With Tempus ECG-Low EF, we're adding another powerful tool to the hands of clinicians to help them identify patients at risk for serious cardiovascular conditions much earlier in their care journey," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. "Detection of LVEF is essential for undiagnosed patients, and this technology enables us to deliver that capability at scale to transform patient care. The addition of a second FDA-cleared Tempus ECG-AI solution reflects our continued commitment to advancing AI-driven cardiology." DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
